Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...

A significant share of Merck’s MRK revenues is derived from the oncology portfolio, led by its blockbuster PD-L1 inhibitor, ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

Merck (NYSE:MRK) received expanded EU approval for KEYTRUDA-based regimens in platinum-resistant ovarian cancer, making it ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

Keytruda, manufactured by the US-based Merck & Co, is an immunotherapy drug that has become one of the world’s best-selling ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells.

With at least seven Indian manufacturers in the race to develop generic versions of Merck & Co’s best-selling cancer ...